Compare BLX & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BLX | PHVS |
|---|---|---|
| Founded | 1977 | 2015 |
| Country | Panama | Switzerland |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 1.8B |
| IPO Year | 1997 | 2020 |
| Metric | BLX | PHVS |
|---|---|---|
| Price | $56.45 | $28.41 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $41.82 |
| AVG Volume (30 Days) | 103.7K | ★ 214.6K |
| Earning Date | 04-27-2026 | 05-12-2026 |
| Dividend Yield | ★ 4.83% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.36 | N/A |
| Revenue Next Year | $9.95 | N/A |
| P/E Ratio | $8.26 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $37.88 | $15.51 |
| 52 Week High | $57.61 | $30.24 |
| Indicator | BLX | PHVS |
|---|---|---|
| Relative Strength Index (RSI) | 71.19 | 52.14 |
| Support Level | $43.50 | $24.55 |
| Resistance Level | N/A | $29.82 |
| Average True Range (ATR) | 1.19 | 1.42 |
| MACD | 0.13 | -0.02 |
| Stochastic Oscillator | 83.99 | 56.08 |
Banco Latinoamericano de Comercio Exterior SA provides financial solutions to financial institutions, companies, and investors doing business in Latin America, supporting trade and regional integration. The Bank provides foreign trade solutions to a select client base of American financial institutions and corporations and has developed a network of correspondent banking institutions with access to the international capital markets. It has two business segments: the Commercial Business Segment and the Treasury Business Segment. The majority of its revenue is generated from the Commercial Business segment.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.